REVELATION BIOSCIENCES, INC. (REVB) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$4.30

From 52W high−87.21%

Volume11228.00

Market cap$2.34M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$4.30

From 52W high

−87.21%

Volume

11228.00

Market cap

$2.34M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.8x

P/E (TTM)

—

RSI (14)

45.0

MomentumView details →

1D Return

−7.05%

YTD Return

−80.80%

SummaryUpdated Jun 1, 2026

Revelation Biosciences, Inc. (NASDAQ:REVB) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in San Diego, California. The company went public in November 2020 and focuses on developing immune system therapeutics and diagnostics. As a relatively young biotech firm, Revelation operates without current revenue generation, dedicating its resources entirely to research and development of novel therapeutic candidates across multiple disease areas including respiratory conditions, chronic organ diseases, and infectious disease diagnostics.

Ask drillr about REVELATION BIOSCIENCES, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.8x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−106.79%

ROA (TTM)

−86.02%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+29.54%

FCF YoY

+46.72%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+72.68%

EBITDA YoY

−34.97%

MomentumView details →

1D Return

−7.05%

YTD Return

−80.80%

1Y Return

−85.78%

RSI (14)

45.0

vs 50D SMA

−22.96%

vs 200D SMA

−45.10%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

6.21x

Quick Ratio

6.21x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.87

EPS Surprise

0.57%

Beats (12Q)

6/12

Next Q EPS Est

−$5.99

Avg Surprise (4Q)

−56.09%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−10.75M

Op. CF (TTM)

−9.33M

Next earningsNov 5, 2026 →

Latest newsMore news →

REVELATION BIOSCIENCES, INC. announced a 1-for-7 reverse stock split of its common stock, effective October 20, 2026.19d ago

Revelation Biosciences, Inc. granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont III as part of their compensation.78d ago

Similar companies

BioXcel Therapeutics, Inc.BTAI HCW Biologics Inc.HCWB CASI Pharmaceuticals, Inc.CASI Silexion Therapeutics Ltd.SLXN Aptevo Therapeutics Inc.APVO BioVie Inc.BIVIW Find similar companies →

Latest newsMore news →

REVELATION BIOSCIENCES, INC. announced a 1-for-7 reverse stock split of its common stock, effective October 20, 2026.19d ago Revelation Biosciences, Inc. granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont III as part of their compensation.78d ago